← Leaderboards
Ravi N Singh
Wake Forest University Health Sciences
$2,961,368
Attributed
$2,961,368
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $511.8K · FY2010–21$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$2,961,368 · 4
By mechanism
R01$1,747,173 · 1
R00$696,985 · 1
P30$260,693 · 1
K99$256,517 · 1
Top collaborators
No co-investigators on record.
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- Fei Xing$1,762,177
- Pameeka S Smith$107,121
- Douglas S. Lyles$15,661,044
- Edward G Shaw$22,365,759
Others in their field
Top investigators on “Future”
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$274,284,003
- Chanza Baytop · Westat, Inc.$271,217,917
- Everette D Joseph · Howard University$246,289,043
Research focus
FutureCell LineBaseCellsCancerousPhenotypeReagentCell Culture TechniquesForestAdenovirusesCustomDoctor Of PhilosophyBiodistributionBloodEquipmentCost EffectiveBaptist ChurchAnticancer ResearchCost SavingsCancer CellCellular EngineeringCancer Center Support GrantCellular TransductionComprehensive Cancer Center
Grant awards (18)
Development of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancer$351,544
R01 · FY2021 · CA · contact PI
Cell Engineering Shared Resource$45,094
P30 · FY2021 · CA · contact PI
Development of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancer$351,544
R01 · FY2020 · CA · contact PI
Cell Engineering Shared Resource$44,837
P30 · FY2020 · CA · contact PI
Development of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancer$340,997
R01 · FY2019 · CA · contact PI
Cell Engineering Shared Resource$105,861
P30 · FY2019 · CA · contact PI
Cell Engineering Shared Resource$29,411
P30 · FY2019 · CA · contact PI
Cell Engineering Shared Resource$14,690
P30 · FY2019 · CA · contact PI
Cell Engineering Shared Resource$11,763
P30 · FY2019 · CA · contact PI
Cell Engineering Shared Resource$5,639
P30 · FY2019 · CA · contact PI
Cell Engineering Shared Resource$3,398
P30 · FY2019 · CA · contact PI
Development of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancer$351,544
R01 · FY2018 · CA · contact PI
Development of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancer$351,544
R01 · FY2017 · CA · contact PI
Tumor Targeting and Diagnostic Applications of Glycosylated Nanotubes$230,797
R00 · FY2014 · CA · contact PI
Tumor Targeting and Diagnostic Applications of Glycosylated Nanotubes$225,885
R00 · FY2013 · CA · contact PI
Tumor Targeting and Diagnostic Applications of Glycosylated Nanotubes$240,303
R00 · FY2012 · CA · contact PI
Tumor Targeting and Diagnostic Applications of Glycosylated Nanotubes$129,695
K99 · FY2011 · CA · contact PI
Tumor Targeting and Diagnostic Applications of Glycosylated Nanotubes$126,822
K99 · FY2010 · CA · contact PI